Can-Fite Biopharma reported mid-year 2025 results alongside several clinical updates: its Phase 2a study of namodenoson in advanced pancreatic adenocarcinoma has passed the 50% enrollment mark, the FDA has authorized the drug for its first single-patient compassionate use in pancreatic cancer with additional U.S. centers seeking access, and new preclinical data from UCLA suggest piclidenoson may restore tissue integrity and function in a vascular dementia model. Financially, the company posted H1 revenue of $0.2 million and a net loss of $4.9 million, ended June with $6.45 million in cash and equivalents, and subsequently raised $5 million in a July offering to support ongoing Phase 3 programs in psoriasis and hepatocellular carcinoma, as well as studies in MASH and pancreatic cancer.
The immediate strategic question is whether Can-Fite can translate a well-established safety profile for its A3 adenosine receptor agonists into clinically persuasive signals in severely refractory populations. Passing 50% enrollment in an open-label pancreatic cancer study is incremental, but compassionate use uptake at prominent U.S. centers could accelerate real-world exposure, create early KOL momentum, and, if coordinated, generate usable evidence that guides trial design and biomarker strategy. In a field where few agents move the needle after first-line, any hint of disease control or survival benefit—even in small datasets—can catalyze partnerships or adaptive combination trials.
For patients and HCPs, the safety and oral dosing of namodenoson offer practical advantages in a high-toxicity setting, but efficacy remains unproven in pancreatic cancer. For payers, orphan designation provides a policy framework for potential exclusivity and premium pricing, yet the value proposition will hinge on robust outcomes versus supportive care or add-on regimens. Medical Affairs teams should prepare for disciplined data capture from compassionate use, including standardized outcomes, patient-reported measures, and potential enrichment based on A3AR expression, to convert anecdotal evidence into decision-grade data. Commercial leaders will read the subdued top line and expanded share count as a signal that Can-Fite may need regional partnerships or co-funding to prosecute multiple pivotal programs, reinforcing the role of BD in advancing this portfolio.
The broader industry context is instructive. Oncology developers are revisiting the adenosine axis, with most activity focusing on A2A/A2B antagonism and CD73 inhibition. A3 agonism represents a differentiated approach with dual anti-inflammatory and antitumor potential. Pancreatic cancer continues to attract novel mechanisms, but success is increasingly found in combinations and biomarker-led cohorts, not monotherapy in late lines. In parallel, the reawakening of interest in neurology—where disease-modifying options remain scarce—makes piclidenoson’s vascular dementia signal notable, albeit early. Dermatology remains crowded with TYK2 inhibitors and biologics; any psoriasis positioning for piclidenoson will likely lean on safety, convenience, and cost in specific patient niches rather than head-to-head superiority.
The financials underscore urgency. With H1 R&D at $3.0 million and G&A at $2.1 million, the recent $5 million raise extends but does not resolve the funding question for multiple mid-to-late-stage programs. The company’s ability to convert pancreatic compassionate use into structured RWE, surface a credible efficacy signal in ongoing trials, and prioritize indications for capital-efficient advancement will determine whether it can attract non-dilutive capital or partnership support. The next inflection is clear: will early, real-world pancreatic data and near-term study readouts be strong enough to unlock a combination strategy or BD deal before the balance sheet forces a narrower focus?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
